We advised the underwriters on the IPO and Nasdaq listing

Davis Polk advised the representatives of the several underwriters in connection with the $500 million initial public offering of 27,878,787 shares of Class A common stock of Recursion Pharmaceuticals, Inc. The shares include 3,636,363 shares sold by Recursion pursuant to the full exercise of the underwriters’ option to purchase additional shares. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol “RXRX.”

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Recursion is headquartered in Salt Lake City, Utah.

The Davis Polk corporate team included partners Alan F. Denenberg and Stephen Salmon, counsel Joseph S. Payne and associate Tomer Magid. The intellectual property and technology transactions team included partner Frank J. Azzopardi and associates S. Dream Montgomery and Daniel P. Kearney. The tax team included counsel Kiara L. Rankin and associate Benjamin Helfgott. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post